AlphaRx Receives Notice of Allowance From the US Patent Office
Tuesday September 12, 8:00 am ET
MARKHAM, ON--(MARKET WIRE)--Sep 12, 2006 -- AlphaRx Inc. (OTC BB:ALRX.OB - News), an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs, has received a Notice of Allowance from the United States Patent and Trademark Office for its patent application entitled ``Stabilization of Benzoyl Peroxide in Solution.``
ADVERTISEMENT
Benzoyl peroxide (``BP``) is one of the most widely used compounds for acne treatment due to its significant antimicrobial activity, mild keratolytic and duct opening properties. The actions include a topical antimicrobial effect against infecting bacteria, the removal of the horny layer of the epidermis, as well as the removal of thickened sebum and other debris clogging follicular pores.
Benzoyl peroxide is water insoluble and this insolubility causes local skin irritation due to contact with crystalline benzoyl peroxide. This insolubility also markedly decreases benzoyl peroxide`s oxidative action. Benzoyl peroxide in solution is much more efficient than micronized BP suspensions for superficial treatment, but once dissolved, the BP in solution becomes extremely unstable.
